Elexacaftor manufacturers

About elexacaftor

Elexacaftor manufacturers are limited to the originator, Vertex Pharmaceuticals, which uses it only in Trikafta (Kaftrio in the EU), combined with tezacaftor and ivacaftor. Elexacaftor is a next-generation CFTR corrector. Trikafta was the first CFTR modulator that could treat about 90% of people with cystic fibrosis, including those with one F508del mutation. It is the world's best-selling cystic fibrosis drug. No generic is approved in the US or EU.

Elexacaftor key facts

Elexacaftor manufacturers and licensing history

Vertex developed elexacaftor as a corrector that works together with tezacaftor and ivacaftor. The FDA approved Trikafta in October 2019, and the EU approved it as Kaftrio in 2020. It was the first CFTR modulator that could treat patients with only one F508del mutation, which made it suitable for about 90% of people with cystic fibrosis.

Trikafta generated about USD 11 billion in sales in 2024. Vertex has since extended it to younger children and additional responsive mutations. Its successor, Alyftrek, was approved in the US in December 2024 and in the EU in July 2025, and is expected to gradually take over.

No generic elexacaftor product is approved in the US or EU. Analysts expect Trikafta to lose patent protection in 2037. Generic developers would need to match a complex three-drug fixed-dose combination.

Elexacaftor dosage forms and dossier types

Elexacaftor is available only in Trikafta / Kaftrio tablets and granules, used with a separate ivacaftor dose.

Elexacaftor regulatory and patent status

The FDA approved Trikafta in October 2019, and the EU approved Kaftrio in 2020. The US label has been extended to children aged 2 and older and to additional responsive mutations. Analysts estimate protection to 2037. No generic is approved in the US or EU, so check patent and exclusivity status before development.

Elexacaftor mechanism of action and therapeutic use

Elexacaftor and tezacaftor are correctors that bind to different sites on the CFTR protein, helping it fold and reach the cell surface. Ivacaftor is a potentiator that helps the channel open. Together, they restore CFTR function and improve lung function, sweat chloride and nutritional status. Trikafta is used for cystic fibrosis in patients with at least one F508del or other responsive mutation.

Elexacaftor licensing and sourcing

Elexacaftor is currently available only from Vertex, in Trikafta / Kaftrio. Companies interested in this molecule usually prepare future generic dossiers or API supply. Current offers and contacts are listed among the elexacaftor manufacturers on Pipelinepharma.

Frequently asked questions about elexacaftor

Who manufactures elexacaftor? Vertex Pharmaceuticals is the only manufacturer and uses elexacaftor in Trikafta (Kaftrio in the EU).

Is elexacaftor available on its own? No. Elexacaftor is sold only in Trikafta / Kaftrio, combined with tezacaftor and ivacaftor.

Is there a generic version of elexacaftor? No. No generic elexacaftor product is approved in the US or EU, and patents are expected to run to about 2037.

What forms and strengths of elexacaftor are available? Elexacaftor is available in tablets of 100/50/75 mg and 50/25/37.5 mg (with tezacaftor and ivacaftor), and in granules for young children.

What is replacing Trikafta? Vertex's Alyftrek, a once-daily combination of vanzacaftor, tezacaftor and deutivacaftor, was approved in the US in December 2024 and the EU in July 2025.